Norbert VEY
MD
-
General Director at Institut Paoli Calmettes | Professor of Hematology at Aix-Marseille University
AMU, IPC
The new immunotherapy antibodies currently developed by biotech companies from Marseille reflect the teams' dynamism and the extraordinary local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the creatity and efficiency of the Marseille’s network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and highly innovative approaches in immunotherapy, based on these three pillars. New molecules currently developed by biotech companies from Marseille reflect the teams’ dynamism and the extraordinary local potential.
#clinique #rechercheHave a look on our testimonies
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.
Daniel OLIVE
AMU, IPC, CRCM
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
Vincent FERT
Veracyte
Cell- and tissue- based therapies and gene therapies hold great promise in the field of both immunotherapy and regenerative medicine.
Christian CHABANNON
AMU, IPC, AP-HM, Inserm
The new immunotherapy antibodies currently developed by biotech companies from Marseille reflect the teams' dynamism and the extraordinary local potential.
Norbert VEY
AMU, IPC
your commitment to MI